- Home
- DJT vs AUPH Comparison
DJT vs AUPH Comparison
Compare DJT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DJT | AUPH |
|---|---|---|
| Founded | 2021 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | DJT | AUPH |
|---|---|---|
| Price | $5.73 | $16.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $18.29 |
| AVG Volume (30 Days) | ★ 4.1M | 742.5K |
| Earning Date | 11-13-2026 | 10-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.76 |
| Revenue | $3,682,600.00 | ★ $283,055,000.00 |
| Revenue This Year | N/A | $16.65 |
| Revenue Next Year | N/A | $17.73 |
| P/E Ratio | ★ N/A | $21.93 |
| Revenue Growth | ★ 1.76 | N/A |
| 52 Week Low | $5.40 | $13.34 |
| 52 Week High | $17.09 | $19.25 |
Technical Indicators
Market Signals| Indicator | DJT | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 27.07 | 43.53 |
| Support Level | N/A | $15.27 |
| Resistance Level | $9.68 | $16.48 |
| Average True Range (ATR) | 0.38 | 0.48 |
| MACD | -0.08 | -0.04 |
| Stochastic Oscillator | 17.31 | 17.38 |
Price Performance
Historical ComparisonAbout DJT Trump Media & Technology Group Corp.
Trump Media & Technology Group Corp is a media and technology company rooted in social media, digital streaming, information technology infrastructure, and more. Its initial product launch will focus on its social media platform, Truth Social, which encourages an open, free, and honest conversation without discriminating against political ideology.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.